Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that improves near vision without affecting distance vision. The drug, marketed as RYZUMVI in the U.S., is now approved for both presbyopia and pharmacologically-induced mydriasis. This milestone highlights Opus Genetics' growing role in innovative eye treatments and triggers a milestone payment from their commercial partner Viatris.
Opus Genetics' FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia offers context for health sector investors. For readers following the health sector, here is Pluang's market snapshot as of Oct 16, 2026 19:42 WIB: Of 150 priced US health stocks tradable on Pluang, 96 rose and 43 fell today. Notable movers include ACADIA Pharmaceuticals Inc. (ACAD) at USD 19.99 with a 1-day change of +1.42% and a typical hold time of 77 days, Hims and Hers Health Inc (HIMS) at USD 28.97 down 1.40% with a 21-day hold time, and Amneal Pharmaceuticals Inc. Class A (AMRX) at USD 19.50 up 1.30% with a 7-day hold time.
K2 Vision has completed over 5,000 procedures using the Light Adjustable Lens (LAL), making it the highest-volume practice worldwide for this technology. The LAL is unique because it can be adjusted after implantation to fine-tune vision based on the...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
BlackRock, Inc. disclosed that its shareholding in Fagron NV dropped below the 3% threshold to 2.96% after selling some voting securities, despite acquiring equivalent financial instruments. As of October 12, 2026, BlackRock holds 2,015,779 voting ri...
Meridian International Center announced its inaugural New Architects of American Influence cohort, recognizing 25 leaders from business, technology, culture, sports, and government who are shaping U.S. global influence. The 2026 cohort includes leade...
M&T Bank reported adjusted earnings per share of $5.08 and revenue of $2.55 billion for Q3 2026, both surpassing analyst estimates. This marks the fourth consecutive quarter the bank has exceeded earnings and revenue expectations, reflecting consiste...
